Compare TLYS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | OTLK |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 37.5M |
| IPO Year | 2011 | 2016 |
| Metric | TLYS | OTLK |
|---|---|---|
| Price | $5.45 | $1.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.00 | ★ $2.50 |
| AVG Volume (30 Days) | 381.4K | ★ 27.0M |
| Earning Date | 06-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $4.66 | $1,430.98 |
| Revenue Next Year | $1.74 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $0.16 |
| 52 Week High | $5.90 | $3.39 |
| Indicator | TLYS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 82.83 |
| Support Level | $3.62 | $1.13 |
| Resistance Level | $5.72 | $1.54 |
| Average True Range (ATR) | 0.45 | 0.15 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 70.83 | 86.63 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.